TY - JOUR
T1 - Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms
AU - Kleven, Mark D.
AU - Jue, Shall
AU - Enns, Caroline A.
N1 - Funding Information:
NIH T-32 Training Grant GMMBI0231C (M.D.K.); NIH R01DK072166 and OHSU Center for Spatial Systems Biomedicine (C.A.E.).
Funding Information:
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Funding NIH T-32 Training Grant GMMBI0231C (M.D.K.); NIH R01DK072166 and OHSU Center for Spatial Systems Biomedicine (C.A.E.). Notes The authors declare no competing financial interest.
Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/3/6
Y1 - 2018/3/6
N2 - Hereditary hemochromatosis (HH), a disease marked by chronic iron overload from insufficient expression of the hormone hepcidin, is one of the most common genetic diseases. One form of HH (type III) results from mutations in transferrin receptor-2 (TfR2). TfR2 is postulated to be a part of signaling system that is capable of modulating hepcidin expression. However, the molecular details of TfR2's role in this system remain unclear. TfR2 is predicted to bind the iron carrier transferrin (Tf) when the iron saturation of Tf is high. To better understand the nature of these TfR-Tf interactions, a binding study with the full-length receptors was conducted. In agreement with previous studies with truncated forms of these receptors, holo-Tf binds to the TfR1 homologue significantly stronger than to TfR2. However, the binding constant for Tf-TfR2 is still far above that of physiological holo-Tf levels, inconsistent with the hypothetical model, suggesting that other factors mediate the interaction. One possible factor, apo-Tf, only weakly binds TfR2 at serum pH and thus will not be able to effectively compete with holo-Tf. Tf binding to a TfR2 chimera containing the TfR1 helical domain indicates that the differences in the helical domain account for differences in the on rate of Tf, and nonconserved inter-receptor interactions are necessary for the stabilization of the complex. Conserved residues at one possible site of stabilization, the apical arm junction, are not important for TfR1-Tf binding but are critical for the TfR2-Tf interaction. Our results highlight the differences in Tf interactions with the two TfRs.
AB - Hereditary hemochromatosis (HH), a disease marked by chronic iron overload from insufficient expression of the hormone hepcidin, is one of the most common genetic diseases. One form of HH (type III) results from mutations in transferrin receptor-2 (TfR2). TfR2 is postulated to be a part of signaling system that is capable of modulating hepcidin expression. However, the molecular details of TfR2's role in this system remain unclear. TfR2 is predicted to bind the iron carrier transferrin (Tf) when the iron saturation of Tf is high. To better understand the nature of these TfR-Tf interactions, a binding study with the full-length receptors was conducted. In agreement with previous studies with truncated forms of these receptors, holo-Tf binds to the TfR1 homologue significantly stronger than to TfR2. However, the binding constant for Tf-TfR2 is still far above that of physiological holo-Tf levels, inconsistent with the hypothetical model, suggesting that other factors mediate the interaction. One possible factor, apo-Tf, only weakly binds TfR2 at serum pH and thus will not be able to effectively compete with holo-Tf. Tf binding to a TfR2 chimera containing the TfR1 helical domain indicates that the differences in the helical domain account for differences in the on rate of Tf, and nonconserved inter-receptor interactions are necessary for the stabilization of the complex. Conserved residues at one possible site of stabilization, the apical arm junction, are not important for TfR1-Tf binding but are critical for the TfR2-Tf interaction. Our results highlight the differences in Tf interactions with the two TfRs.
UR - http://www.scopus.com/inward/record.url?scp=85043347087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043347087&partnerID=8YFLogxK
U2 - 10.1021/acs.biochem.8b00006
DO - 10.1021/acs.biochem.8b00006
M3 - Article
C2 - 29388418
AN - SCOPUS:85043347087
SN - 0006-2960
VL - 57
SP - 1552
EP - 1559
JO - Biochemistry
JF - Biochemistry
IS - 9
ER -